A top BIO official said a sudden change of rules in Japan will make the country “less predictable and more risky for innovators” going forward.

India's Sun Pharma is joining the trend to build a portfolio in Russia with a deal worth $60 million to buy control of a Russian drug producer.

Chinese authorities have halted drug manufacturing in the northern city of Shijiazhuang as part of a crackdown on pollution. The shuttering of the three plants…

In this week's FiercePharmaAsia wrap-up, China has become first to test CRISPR in human, GSK is being sued by private investigators, and more.

A few years ago, emerging markets were souped-up engines heating up pharma growth. Now, with economic slowdowns in key markets such as China, they’ve moved…

Years removed from a bruising bribery scandal, GlaxoSmithKline now wins awards for corporate behavior. But a new lawsuit may bring the scandal back to the fore.

For the second time in recent weeks, the FDA has slapped a Japanese API maker with a warning letter, this time for data integrity problems at Sekisui Medical.

To get its dengue vaccine candidate into a 20,000-patient Phase III study, Takeda's vax unit had to stoke up a global growth spurt.

Pharma Asia